Pharma Stock Reports 37.70% YoY Rise in Net Profit; Revenue Up 13.49% in Q3FY26
Kiran DSIJ / 13 Feb 2026 / Categories: Mindshare, Trending
The stock is up by 44.3 per cent from its 52-week low of Rs 440 per share.
Lincoln Pharmaceuticals Limited (BSE: 531633, NSE: LINCOLN) delivered a robust financial performance for the third quarter of FY 2025-26, highlighted by a 37.70 per cent year-on-year surge in consolidated net profit to Rs 28.60 crore. Revenue from operations for the quarter climbed to Rs 166.32 crore, up from Rs 146.55 crore in the previous year's corresponding period. This growth was accompanied by a solid operational showing, with EBITDA rising 18.73 per cent to Rs 38.74 crore and an Earnings Per Share (EPS) of Rs 14.28 for the quarter.
The company's nine-month performance ending December 2025 also remains on an upward trajectory, with a consolidated net profit of Rs. 76.26 crore on revenues of Rs 483.75 crore. This financial stability is reinforced by CRISIL Ratings' recent reaffirmation of its ‘CRISIL A/Stable/CRISIL A1’ ratings. The rating agency pointed to the promoters' extensive industry experience and the company's healthy financial profile as key strengths, which help mitigate challenges related to working-capital intensity and a competitive regulatory environment.
Looking ahead, Lincoln Pharmaceuticals has set an ambitious target of Rs 1,000 crore in revenue within the next three years. To achieve a projected annual growth rate of 15-18 per cent, the company is focusing on high-value product lines and expansion within the cardiac, diabetic, dermatology, and ENT segments. With Foreign Institutional Investors (FIIs) holding a 4.70 per cent stake as of December 2025, the company continues to focus on broadening its global footprint and entering new markets to meet diverse healthcare demands.
About the Company
Lincoln Pharmaceuticals Ltd, established in 1979, manufactures and trades pharmaceutical products. The company offers over 600 formulations across 15 therapeutic areas, with 1700 registered products and 700 more in development. They hold 7 patents and have applied for over 25 additional ones, covering a wide range of therapeutic needs from dermatology and gynaecology to anti-infectives and cardiac medications.
The company has a market cap of over Rs 1,270 crore with a PE of 14x whereas the industry PE is 30x. The stock has an ROE of 13 per cent and an ROCE of 18 per share. The stock is up by 44.3 per cent from its 52-week low of Rs 440 per share.
Disclaimer: The article is for informational purposes only and not investment advice.